{
    "clinical_study": {
        "@rank": "148256", 
        "brief_summary": {
            "textblock": "RATIONALE: Screening tests may help doctors detect cancer cells early and plan more\n      effective treatment for ovarian cancer.\n\n      PURPOSE: Screening trial to determine the best procedure to detect ovarian cancer in women\n      who have a high genetic risk for developing ovarian cancer."
        }, 
        "brief_title": "Screening Women at High Genetic Risk for Ovarian Cancer", 
        "completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine an optimal screening procedure for ovarian cancer, in terms of the most\n           appropriate screening test, criteria for interpretation of results, and screening\n           intervals, in women at high genetic risk for developing ovarian cancer.\n\n        -  Determine the physical morbidity and the resource implications associated with ovarian\n           cancer screening in these women.\n\n        -  Assess the feasibility of screening this high-risk population in terms of compliance\n           rates.\n\n      OUTLINE: Patients undergo transvaginal ultrasonography of the ovaries (scheduled for the\n      early follicular phase, day 3-6 of the menstrual cycle) and CA 125 measurement annually.\n      Blood samples are collected every 4 months for analysis of CA 125 levels and novel markers.\n\n      Peer Reviewed and Funded or Endorsed by Cancer Research UK\n\n      PROJECTED ACCRUAL: A total of 5,000 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  First-degree relative (mother, sister, or daughter) of an affected member of a\n             high-risk family defined as one of the following:\n\n               -  Family containing 2 or more individuals with ovarian cancer who are connected by\n                  first-degree relationships\n\n               -  Family containing 1 individual with ovarian cancer and 1 individual with breast\n                  cancer and under 50 years of age at the time of diagnosis who are connected by\n                  first-degree relationships\n\n               -  Family containing 1 individual with ovarian cancer and 2 individuals with breast\n                  cancer and under 60 years of age at the time of diagnosis who are connected by\n                  first-degree relationships\n\n               -  Family containing an affected individual with a mutation of one of the known\n                  ovarian cancer predisposing genes\n\n               -  Family containing 3 individuals with colorectal cancer with at least 1\n                  individual under 50 years of age at time of diagnosis and 1 individual with\n                  ovarian cancer who are connected by first-degree relationships\n\n               -  Families where affected relatives are related by second-degree relationships\n                  through an unaffected intervening male relative who has an affected daughter are\n                  allowed\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  35 and over\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  Not specified\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  No prior bilateral oophorectomy\n\n        Other:\n\n          -  No concurrent participation in other ovarian cancer screening trials"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "5000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00033488", 
            "org_study_id": "CDR0000069292", 
            "secondary_id": [
                "UKFOCSS", 
                "CRCA-FOCS", 
                "EU-20044"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "cytology specimen collection procedure", 
                "intervention_type": "Other"
            }, 
            {
                "intervention_name": "annual screening", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "comparison of screening methods", 
                "intervention_type": "Procedure"
            }
        ], 
        "keyword": "ovarian epithelial cancer", 
        "lastchanged_date": "December 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UKFOCSS"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "WC1N 1EH"
                    }, 
                    "name": "Institute of Child Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "EC1A 7BE"
                    }, 
                    "name": "Saint Bartholomew's Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "official_title": "The UK Familial Ovarian Cancer Screening Study", 
        "overall_official": {
            "affiliation": "Institute of Child Health", 
            "last_name": "James Mackay, MD, MA, FRCP, FRCPE", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00033488"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University College London Hospitals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2000", 
        "study_design": "Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "June 2007"
    }, 
    "geocoordinates": {
        "Institute of Child Health": "51.508 -0.128", 
        "Saint Bartholomew's Hospital": "51.508 -0.128"
    }
}